Skip to Main Content
Table 3.

Patient characteristics and distribution of AI and CTCs in blood

Clinical parametersPatients totalNo. of patients with
AI*CTCs*
Diagnosis subgroup    
    M0 69 (85.0%) 31 (45.0%) 49 (71.0%) 
    M1 12 (15.0%) 7 (58.5%) 11 (92.0%) 
    Total 81 (100%) 38 (47.0%) 60 (74.0%) 
Tumor stage    
    pT1-pT2 40 (54.0%) 16 (40.0%) 27 (67.5%) 
    pT3-pT4 34 (46.0%) 18 (53.0%) 28 (82.5%) 
    Total 74 (100%) 34 (46.0%) 55 (74.5%) 
Gleason score    
    ≤3+4 41 (54.0%) 18 (44.0%) 28 (68.5%) 
    ≥4+3 35 (46.0%) 18 (51.5%) 29 (83.0%) 
    Total 76 (100%) 36 (47.5%) 57 (75.0%) 
tPSA*%fPSA values    
    Low risk 22 (32.0%) 11 (50.0%) 17 (77.5%) 
    High risk§ 47 (68.0%) 22 (47.0%) 34 (72.5%) 
    Total 69 (100%) 33 (48.0%) 51 (74.0%) 
Clinical parametersPatients totalNo. of patients with
AI*CTCs*
Diagnosis subgroup    
    M0 69 (85.0%) 31 (45.0%) 49 (71.0%) 
    M1 12 (15.0%) 7 (58.5%) 11 (92.0%) 
    Total 81 (100%) 38 (47.0%) 60 (74.0%) 
Tumor stage    
    pT1-pT2 40 (54.0%) 16 (40.0%) 27 (67.5%) 
    pT3-pT4 34 (46.0%) 18 (53.0%) 28 (82.5%) 
    Total 74 (100%) 34 (46.0%) 55 (74.5%) 
Gleason score    
    ≤3+4 41 (54.0%) 18 (44.0%) 28 (68.5%) 
    ≥4+3 35 (46.0%) 18 (51.5%) 29 (83.0%) 
    Total 76 (100%) 36 (47.5%) 57 (75.0%) 
tPSA*%fPSA values    
    Low risk 22 (32.0%) 11 (50.0%) 17 (77.5%) 
    High risk§ 47 (68.0%) 22 (47.0%) 34 (72.5%) 
    Total 69 (100%) 33 (48.0%) 51 (74.0%) 
*

Detection of one or more AI and CTCs was considered as positive.

tPSA*%fPSA, a combination of tPSA and %fPSA values.

Low-risk tPSA*%fPSA values: tPSA = 4-10 ng/mL plus fPSA>15% and tPSA>10 ng/mL plus fPSA>21%.

§

High-risk tPSA*%fPSA values: tPSA = 4-10 ng/mL plus fPSA<15% and tPSA>10 ng/mL plus fPSA<10%.

Close Modal

or Create an Account

Close Modal
Close Modal